Jim Momtazee's Patient Square leads $150M+ addition to Kriya Therapeutics' 'mainstream' gene therapy ambitions

Shankar Ramaswamy’s Kriya Therapeutics has upped its Series C with an additional $150 million-plus to take the biotech into late 2026.

The AAV-focused gene therapy …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions